HPV vaccines for adults over age 26 may not be cost-effective
Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots
11 March 2021Messenger RNA COVID-19 vaccines greatly reduce risk of asymptomatic COVID-19 infection, spread to ot
11 March 2021HPV vaccines for adults over age 26 may not be cost-effective
Vaccinating adults age 26 and older against the human papillomavirus (HPV)—the virus that causes more than 90% of cervical cancers as well as several other cancers—may not be cost-effective, according to a new study led by researchers at the Harvard T.H. School of Public Health.
